News and Events – Chimeric Therapeutics

Press Releases

May 2022

Chimeric Exercises Option for CORE-NK Cell Platform

April 2022

Strategic Manufacturing Partnership with WuXi Advanced Therapies

March 2022

CDH17 CAR T Preclinical Data featured as cover story for prestigious journal Nature Cancer

March 2022

Final Results in Phase I Trial of CORE NK Platform

March 2022

CORE NK Platform Phase I Clinical Data Presentation

March 2022

CHM Partners with Be The Match Biotherapies to Advance CHM1101 (CLTX CAR T)

March 2022

Letter to Shareholders – Rights Issue 1 March 2022

February 2022

3rd Dose Level Initiated in CLTX CAR T Phase I Trial

February 2022

Prospectus Accelerated Non-Renounceable Pro Rata Entitlement Offer

February 2022

Entitlement Offer to Raise Approximately $18.1million

February 2022

Encouraging Data from 2nd Dose Cohort in CLTX CAR T Trial

February 2022

Kelly Thornburg appointed Vice President, Head of Quality

January 2022

Sponsored Research Agreement with University of Pennsylvania

January 2022

CHM receives US Patent covering CLTX CAR Technology

Events and Presentations

November 2021

CHM 1101 (CLTX CAR T) Presents Positive Initial Phase 1 Clinical Data

November 2021

CHM 1101 (CLTX CAR T) Phase 1 Initial Data Release Presentation

October 2021

CEO Jennifer Chow’s presentation at AusBiotech Conference 2021

October 2021

CHM Virtual User Meeting Guide 2021

October 2021

CHM Notice of 2021 AGM & Proxy Form

September 2021

ASX Small and Mid Cap Conference – Jennifer Chow, Chimeric CEO – Tuesday, September 14

Recent Media Coverage

February 2022

CEO Jennifer Chow Presents at the FNN Investor Event Feb 2022

February 2022

Paul Hopper speaks to Matt Birney from Bulls N’ Bears

February 2022

CEO Jennifer Chow interviewed on Stockhead Feb 2022

February 2022

CEO Jennifer Chow interviewed on RAAS Feb 2022

February 2022

CEO Jennifer Chow interviewed on Proactive Investors Feb 2022

February 2022

CEO Jennifer Chow interviewed on Financial News Network Feb 2022

December 2021

CEO Interview on Positive Initial Phase 1 Clinical Data

November 2021

Rat’s Rant – The Godzilla Edition Chimeric Therapeutics (small cap CAR T bio tech play)

September 2021

Boardroom Media

September 2021

Rat’s Rant – Chimeric Therapeutics is the August Pick of the Month

Media Resources

“How Dose CAR T Work” Infographic

Background to CLTX CAR T

Background to CDH17 CAR T